President Trump plans to impose escalating tariffs on imported generic medicines, starting at 100% in August 2028 and rising to 200% a year later. This move aims to encourage pharmaceutical manufacturing within the U.S., but it has drawn criticism from medical professionals who warn of potential cost increases and drug shortages. Indian drug manufacturers, a major supplier of generics to the U.S., are particularly concerned about this policy shift.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
0
Ali NematiWritten by Ali
